RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

10X Genomics ROE 2024

10X Genomics ROE

-0.34

10X Genomics Dividend yield

Ticker

TXG

ISIN

US88025U1097

WKN

A2PPQJ

In 2024, 10X Genomics's return on equity (ROE) was -0.34, a 67.08% increase from the -0.21 ROE in the previous year.

10X Genomics Aktienanalyse

What does 10X Genomics do?

10X Genomics is a US-based company specializing in the development of life science products. It was founded in 2012 by Serge Saxonov and Ben Hindson and is headquartered in Pleasanton, California. The company's business model focuses on providing technology platforms that enable researchers and scientists to analyze and understand complex biological data. It combines microfluidics, genomics, and bioinformatics. 10X Genomics is divided into different divisions, each focusing on different products and applications: Single-Cell Genomics, Long-Read Sequencing, Immune Profiling, and Spatial Transcriptomics. The company's products include the Chromium platform for cell type identification, disease research, and drug screening; Long-Read Sequencing technology for reading larger DNA fragments; tools and solutions for immune profiling and understanding the immune system; and Spatial Transcriptomics technology for studying the spatial organization of gene expression in tissues. 10X Genomics also offers other products and solutions in the field of genomic sequencing and analysis, including DNA preparation and sequencing kits, software for DNA data analysis and interpretation, and consulting and training services. The company has received various awards and recognition for its innovative approach, including the Innovation Award from The Scientist magazine and the Disruptive Technology Award from the Wall Street Journal. Overall, 10X Genomics has become a leading company in the life science industry, contributing to the advancement of scientific understanding and supporting progress in medicine and biotechnology. 10X Genomics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding 10X Genomics's Return on Equity (ROE)

10X Genomics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing 10X Genomics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

10X Genomics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in 10X Genomics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about 10X Genomics Stock

What is the ROE (Return on Equity) of 10X Genomics this year?

The ROE of 10X Genomics this year is -0.34 undefined.

How has the Return on Equity (ROE) of 10X Genomics developed compared to the previous year?

The ROE of 10X Genomics has increased by 67.08% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of 10X Genomics?

A high ROE indicates that 10X Genomics generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of 10X Genomics?

A low ROE can indicate that 10X Genomics is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of 10X Genomics affect the company?

A change in ROE (Return on Equity) of 10X Genomics can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of 10X Genomics?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of 10X Genomics?

Some factors that can influence 10X Genomics's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does 10X Genomics pay?

Over the past 12 months, 10X Genomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, 10X Genomics is expected to pay a dividend of 0 USD.

What is the dividend yield of 10X Genomics?

The current dividend yield of 10X Genomics is .

When does 10X Genomics pay dividends?

10X Genomics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of 10X Genomics?

10X Genomics paid dividends every year for the past 0 years.

What is the dividend of 10X Genomics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is 10X Genomics located?

10X Genomics is assigned to the 'Health' sector.

Wann musste ich die Aktien von 10X Genomics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of 10X Genomics from 4/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/26/2024.

When did 10X Genomics pay the last dividend?

The last dividend was paid out on 4/26/2024.

What was the dividend of 10X Genomics in the year 2023?

In the year 2023, 10X Genomics distributed 0 USD as dividends.

In which currency does 10X Genomics pay out the dividend?

The dividends of 10X Genomics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von 10X Genomics

Our stock analysis for 10X Genomics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of 10X Genomics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.